Coronavirus
Learn how KU is responding to the COVID-19 pandemic in a way that benefits Kansas and society.
Stay updated with breaking news from Adapt Out. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Learn how KU is responding to the COVID-19 pandemic in a way that benefits Kansas and society.
Share this article Share this article SCHAUMBURG, Ill., Feb. 12, 2021 /PRNewswire/ -- Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that Camostat mesilate (Camostat), is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID), which was launched by the National Institutes of Health (NIH) and the AIDS Clinical Trials Group (ACTG) in May 2020. ACTG was tasked with leading a Master Adaptive protocol under the Accelerating COVID-19 Therapeutic Interventions and Vaccine (ACTIV) partnership by ...